Sökning: onr:"swepub:oai:DiVA.org:hkr-20859" > Apomorphine formula...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04970naa a2200661 4500 | |
001 | oai:DiVA.org:hkr-20859 | |
003 | SwePub | |
008 | 200703s2020 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:144085273 | |
024 | 7 | a urn:nbn:se:hkr:diva-208592 urn |
024 | 7 | a https://doi.org/10.1007/s00415-020-10031-12 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1440852732 URI |
040 | a (SwePub)hkrd (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Hagell, Peteru Högskolan Kristianstad,Forskningsmiljön PRO-CARE, Patient Reported Outcomes - Clinical Assessment Research and Education,Avdelningen för sjuksköterskeutbildningarna och integrerad hälsovetenskap4 aut0 (Swepub:hkr)hape |
245 | 1 0 | a Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease |
264 | 1 | c 2020 |
338 | a print2 rdacarrier | |
506 | a gratis | |
520 | a Continuous subcutaneous (s.c.) apomorphine infusion is an effective therapy for Parkinson's disease (PD), but a limitation is the formation of troublesome s.c. nodules. Various chemically non-identical apomorphine formulations are available. Anecdotal experiences have suggested that shifting from one of these (Apo-Go PumpFill®; apoGPF) to another (Apomorphine PharmSwed®; apoPS) may influence the occurrence and severity of s.c. nodules. We, therefore, followed 15 people with advanced PD (median PD-duration, 15 years; median "off"-phase Hoehn and Yahr, IV) on apoGPF and with troublesome s.c. nodules who were switched to apoPS. Data were collected at baseline, at the time of switching, and at a median of 1, 2.5, and 7.3 months post-switch. Total nodule numbers (P < 0.001), size (P < 0.001), consistency (P < 0.001), skin changes (P = 0.058), and pain (P ≤ 0.032) improved over the observation period. PD severity and dyskinesias tended to improve and increase, respectively. Apomorphine doses were stable, but levodopa doses increased by 100 mg/day. Patient-reported apomorphine efficacy tended to increase and all participants remained on apoPS throughout the observation period; with the main patient-reported reason being improved nodules. These observations suggest that patients with s.c. nodules caused by apoGPF may benefit from switching to apoPS in terms of s.c. nodule occurrence and severity. Alternatively, observed benefits may have been due to the switch itself. As nodule formation is a limiting factor in apomorphine treatment, a controlled prospective study comparing local tolerance with different formulations is warranted. | |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
653 | a Apomorphin; Complications; Nodules; Parkinson’s disease; Safety; Skin | |
700 | 1 | a Höglund, Arjau Karolinska universitetssjukhuset4 aut |
700 | 1 | a Hellqvist, Carinau Universitetssjukhuset i Linköping4 aut |
700 | 1 | a Johansson, Eva-Lenau Centralsjukhuset i Karlstad4 aut |
700 | 1 | a Löwed, Beritu Centralsjukhuset i Karlstad4 aut |
700 | 1 | a Sjöström, Anne-Christineu Sahlgrenska universitetsjukhuset4 aut |
700 | 1 | a Karlberg, Carinau Sahlgrenska universitetsjukhuset4 aut |
700 | 1 | a Lundgren, Margarethu Karolinska universitetssjukhuset4 aut |
700 | 1 | a Dizdar, Nilu Linköpings universitet4 aut |
700 | 1 | a Johansson, Andersu Karolinska universitetssjukhuset4 aut |
700 | 1 | a Willows, Thomasu Karolinska universitetssjukhuset4 aut |
700 | 1 | a Rådberg, Johanu Centralsjukhuset i Karlstad4 aut |
700 | 1 | a Bergquist, Filipu Sahlgrenska universitetssjukhuset4 aut |
700 | 1 | a Karlberg, C4 aut |
700 | 1 | a Hellqvist, C4 aut |
700 | 1 | a Lowed, B4 aut |
700 | 1 | a Willows, T4 aut |
700 | 1 | a Radberg, J4 aut |
700 | 1 | a Bergquist, F4 aut |
700 | 1 | a Dizdar, N4 aut |
700 | 1 | a Hoglund, Au Karolinska Institutet4 aut |
700 | 1 | a Lundgren, M4 aut |
700 | 1 | a Hagell, P4 aut |
700 | 1 | a Sjostrom, AC4 aut |
700 | 1 | a Johansson, EL4 aut |
700 | 1 | a Johansson, Au Karolinska Institutet4 aut |
710 | 2 | a Högskolan Kristianstadb Forskningsmiljön PRO-CARE, Patient Reported Outcomes - Clinical Assessment Research and Education4 org |
773 | 0 | t Journal of Neurologyg 267:11, s. 3411-3417q 267:11<3411-3417x 0340-5354x 1432-1459 |
856 | 4 | u https://doi.org/10.1007/s00415-020-10031-1y Fulltext |
856 | 4 | u https://link.springer.com/content/pdf/10.1007/s00415-020-10031-1.pdf |
856 | 4 8 | u http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-20859x lärosäteslänky Till lärosätets (hkr) databas |
856 | 4 8 | u https://doi.org/10.1007/s00415-020-10031-1 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:144085273 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy